BlackRock’s Recursion Pharmaceuticals RXRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $144M | Buy |
28,371,063
+4,864,474
| +21% | +$24.6M | ﹤0.01% | 1801 |
|
|
2025
Q1 | $124M | Buy |
23,506,589
+69,953
| +0.3% | +$370K | ﹤0.01% | 1853 |
|
|
2024
Q4 | $158M | Buy |
23,436,636
+2,693,839
| +13% | +$18.2M | ﹤0.01% | 1783 |
|
|
2024
Q3 | $137M | Buy |
20,742,797
+3,432,635
| +20% | +$22.6M | ﹤0.01% | 1885 |
|
|
2024
Q2 | $130M | Buy |
17,310,162
+4,989,127
| +40% | +$37.4M | ﹤0.01% | 1865 |
|
|
2024
Q1 | $123M | Sell |
12,321,035
-72,837
| -0.6% | -$726K | ﹤0.01% | 1929 |
|
|
2023
Q4 | $122M | Buy |
12,393,872
+536,918
| +5% | +$5.29M | ﹤0.01% | 1939 |
|
|
2023
Q3 | $90.7M | Buy |
11,856,954
+237,527
| +2% | +$1.82M | ﹤0.01% | 2027 |
|
|
2023
Q2 | $86.8M | Buy |
11,619,427
+987,570
| +9% | +$7.38M | ﹤0.01% | 2110 |
|
|
2023
Q1 | $70.9M | Sell |
10,631,857
-35,767
| -0.3% | -$239K | ﹤0.01% | 2200 |
|
|
2022
Q4 | $82.2M | Buy |
10,667,624
+900,584
| +9% | +$6.94M | ﹤0.01% | 2119 |
|
|
2022
Q3 | $104M | Buy |
9,767,040
+1,525,258
| +19% | +$16.2M | ﹤0.01% | 1919 |
|
|
2022
Q2 | $67.1M | Buy |
8,241,782
+1,534,025
| +23% | +$12.5M | ﹤0.01% | 2268 |
|
|
2022
Q1 | $48M | Sell |
6,707,757
-54,927
| -0.8% | -$393K | ﹤0.01% | 2576 |
|
|
2021
Q4 | $116M | Buy |
6,762,684
+4,995,020
| +283% | +$85.6M | ﹤0.01% | 2102 |
|
|
2021
Q3 | $40.7M | Buy |
1,767,664
+323,586
| +22% | +$7.45M | ﹤0.01% | 2760 |
|
|
2021
Q2 | $52.7M | Buy |
+1,444,078
| New | +$52.7M | ﹤0.01% | 2627 |
|